Pharmacophore Modeling and Virtual Screening for Novel Acidic Inhibitors of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1)

Microsomal prostaglandin E2 synthase-1 (mPGES-1) catalyzes prostaglandin E2 formation and is considered as a potential anti-inflammatory pharmacological target. To identify novel chemical scaffolds active on this enzyme, two pharmacophore models for acidic mPGES-1 inhibitors were developed and theoretically validated using information on mPGES-1 inhibitors from literature. The models were used to screen chemical databases supplied from the National Cancer Institute (NCI) and the Specs. Out of 29 compounds selected for biological evaluation, nine chemically diverse compounds caused concentration-dependent inhibition of mPGES-1 activity in a cell-free assay with IC50 values between 0.4 and 7.9 μM, respectively. Further pharmacological characterization revealed that also 5-lipoxygenase (5-LO) was inhibited by most of these active compounds in cell-free and cell-based assays with IC50 values in the low micromolar range. Together, nine novel chemical scaffolds inhibiting mPGES-1 are presented that may possess anti-inflammatory properties based on the interference with eicosanoid biosynthesis.

[1]  B. Persson,et al.  Common structural features of mapeg—a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism , 2008, Protein science : a publication of the Protein Society.

[2]  P. Jakobsson,et al.  Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. , 2000, European journal of biochemistry.

[3]  S. Laufer,et al.  Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. , 2001, Pharmacological research.

[4]  D. Riendeau,et al.  Inhibition of inducible prostaglandin E2 synthase by 15-deoxy-Δ12,14-prostaglandin J2 and polyunsaturated fatty acids , 2002 .

[5]  Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. , 2002, Biochemical pharmacology.

[6]  O. Werz,et al.  Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. , 2002, Blood.

[7]  Yves Bureau,et al.  Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model , 2003, The Journal of Immunology.

[8]  O. Werz,et al.  Phosphorylation‐ and stimulus‐dependent inhibition of cellular 5‐lipoxygenase activity by nonredox‐type inhibitors , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  W. Schaal,et al.  Indoles useful for the treatment of inflammation. , 2005 .

[10]  N. Méthot,et al.  Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. , 2005, Bioorganic & medicinal chemistry letters.

[11]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[12]  Sunil Badve,et al.  Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy , 2006, The Journal of pathology.

[13]  Seung Joo Cho,et al.  3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors. , 2007, Journal of molecular modeling.

[14]  N. Méthot,et al.  Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[15]  S. Cho,et al.  3D-QSAR study of microsomal prostaglandin E2 synthase(mPGES-1) inhibitors , 2007 .

[16]  Ralf Morgenstern,et al.  Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target , 2007, Pharmacological Reviews.

[17]  O. Werz,et al.  Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9 , 2007, Apoptosis.

[18]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[19]  O. Werz,et al.  Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. , 2008, Journal of medicinal chemistry.

[20]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[21]  Wolfgang Albrecht,et al.  Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[22]  J. Mancini,et al.  Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. , 2008, Journal of medicinal chemistry.

[23]  Chang-Guo Zhan,et al.  Human Microsomal Prostaglandin E Synthase-1 (mPGES-1) Binding with Inhibitors and the Quantitative Structure-Activity Correlation , 2008, J. Chem. Inf. Model..

[24]  O. Werz,et al.  ERK-mediated regulation of leukotriene biosynthesis by androgens: A molecular basis for gender differences in inflammation and asthma , 2008, Proceedings of the National Academy of Sciences.

[25]  Ralf Morgenstern,et al.  Structural basis for induced formation of the inflammatory mediator prostaglandin E2 , 2008, Proceedings of the National Academy of Sciences.

[26]  Sebastian G. Rohrer,et al.  Maximum Unbiased Validation (MUV) Data Sets for Virtual Screening Based on PubChem Bioactivity Data , 2009, J. Chem. Inf. Model..

[27]  Calvin Yu-Chian Chen,et al.  Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping , 2009 .

[28]  G. Schneider,et al.  Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.

[29]  G. Hessler,et al.  The scaffold hopping potential of pharmacophores. , 2010, Drug discovery today. Technologies.